nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—ABCC2—Vincristine—muscle cancer	0.162	0.179	CbGbCtD
Canagliflozin—ABCC2—Etoposide—muscle cancer	0.148	0.164	CbGbCtD
Canagliflozin—ABCC2—Doxorubicin—muscle cancer	0.101	0.112	CbGbCtD
Canagliflozin—ABCC2—Methotrexate—muscle cancer	0.098	0.109	CbGbCtD
Canagliflozin—ABCB1—Dactinomycin—muscle cancer	0.0857	0.0949	CbGbCtD
Canagliflozin—ALB—Methotrexate—muscle cancer	0.0611	0.0677	CbGbCtD
Canagliflozin—ABCB1—Vincristine—muscle cancer	0.0528	0.0585	CbGbCtD
Canagliflozin—ABCB1—Etoposide—muscle cancer	0.0483	0.0536	CbGbCtD
Canagliflozin—ABCB1—Doxorubicin—muscle cancer	0.033	0.0365	CbGbCtD
Canagliflozin—ABCB1—Methotrexate—muscle cancer	0.0319	0.0354	CbGbCtD
Canagliflozin—CYP3A4—Vincristine—muscle cancer	0.0316	0.035	CbGbCtD
Canagliflozin—CYP3A4—Etoposide—muscle cancer	0.029	0.0321	CbGbCtD
Canagliflozin—CYP3A4—Doxorubicin—muscle cancer	0.0198	0.0219	CbGbCtD
Canagliflozin—SLC5A2—renal system—muscle cancer	0.00751	0.138	CbGeAlD
Canagliflozin—SLC5A1—renal system—muscle cancer	0.0057	0.104	CbGeAlD
Canagliflozin—SLC5A2—vagina—muscle cancer	0.00544	0.0997	CbGeAlD
Canagliflozin—SLC5A1—cardiac atrium—muscle cancer	0.0051	0.0934	CbGeAlD
Canagliflozin—SLC5A2—testis—muscle cancer	0.00486	0.089	CbGeAlD
Canagliflozin—UGT2B4—cardiac atrium—muscle cancer	0.0047	0.0861	CbGeAlD
Canagliflozin—SLC5A1—vagina—muscle cancer	0.00413	0.0756	CbGeAlD
Canagliflozin—SLC5A1—testis—muscle cancer	0.00368	0.0674	CbGeAlD
Canagliflozin—UGT1A9—renal system—muscle cancer	0.00358	0.0657	CbGeAlD
Canagliflozin—ABCC2—renal system—muscle cancer	0.00155	0.0284	CbGeAlD
Canagliflozin—Sunburn—Methotrexate—muscle cancer	0.00154	0.0358	CcSEcCtD
Canagliflozin—ORM1—bone marrow—muscle cancer	0.00143	0.0261	CbGeAlD
Canagliflozin—ABCC2—tendon—muscle cancer	0.00121	0.0222	CbGeAlD
Canagliflozin—Rash papular—Doxorubicin—muscle cancer	0.00108	0.0251	CcSEcCtD
Canagliflozin—ALB—testis—muscle cancer	0.00107	0.0196	CbGeAlD
Canagliflozin—ABCC2—testis—muscle cancer	0.001	0.0184	CbGeAlD
Canagliflozin—Urine output increased—Vincristine—muscle cancer	0.000868	0.0201	CcSEcCtD
Canagliflozin—Fracture—Methotrexate—muscle cancer	0.000801	0.0186	CcSEcCtD
Canagliflozin—Multiple fractures—Methotrexate—muscle cancer	0.000801	0.0186	CcSEcCtD
Canagliflozin—Polyuria—Vincristine—muscle cancer	0.000793	0.0184	CcSEcCtD
Canagliflozin—CYP3A4—renal system—muscle cancer	0.000787	0.0144	CbGeAlD
Canagliflozin—Vulvovaginal candidiasis—Doxorubicin—muscle cancer	0.000767	0.0178	CcSEcCtD
Canagliflozin—Vulvovaginal mycotic infection—Doxorubicin—muscle cancer	0.000737	0.0171	CcSEcCtD
Canagliflozin—ABCB1—embryo—muscle cancer	0.000736	0.0135	CbGeAlD
Canagliflozin—Rash maculo-papular—Etoposide—muscle cancer	0.000707	0.0164	CcSEcCtD
Canagliflozin—Serum creatinine increased—Doxorubicin—muscle cancer	0.000655	0.0152	CcSEcCtD
Canagliflozin—Dehydration—Vincristine—muscle cancer	0.000648	0.015	CcSEcCtD
Canagliflozin—ABCB1—renal system—muscle cancer	0.000557	0.0102	CbGeAlD
Canagliflozin—Photosensitivity reaction—Vincristine—muscle cancer	0.00055	0.0127	CcSEcCtD
Canagliflozin—Rash erythematous—Doxorubicin—muscle cancer	0.000526	0.0122	CcSEcCtD
Canagliflozin—Rash pustular—Doxorubicin—muscle cancer	0.000506	0.0117	CcSEcCtD
Canagliflozin—Urinary tract disorder—Vincristine—muscle cancer	0.000476	0.011	CcSEcCtD
Canagliflozin—Urethral disorder—Vincristine—muscle cancer	0.000472	0.011	CcSEcCtD
Canagliflozin—Erythema—Dactinomycin—muscle cancer	0.00047	0.0109	CcSEcCtD
Canagliflozin—Cystitis noninfective—Methotrexate—muscle cancer	0.000455	0.0105	CcSEcCtD
Canagliflozin—Cystitis—Methotrexate—muscle cancer	0.00045	0.0104	CcSEcCtD
Canagliflozin—Vaginal infection—Methotrexate—muscle cancer	0.00044	0.0102	CcSEcCtD
Canagliflozin—Angiopathy—Vincristine—muscle cancer	0.000437	0.0101	CcSEcCtD
Canagliflozin—Nocturia—Doxorubicin—muscle cancer	0.000435	0.0101	CcSEcCtD
Canagliflozin—ABCB1—bone marrow—muscle cancer	0.000421	0.00772	CbGeAlD
Canagliflozin—Urine output increased—Methotrexate—muscle cancer	0.000421	0.00976	CcSEcCtD
Canagliflozin—Bladder pain—Methotrexate—muscle cancer	0.000421	0.00976	CcSEcCtD
Canagliflozin—ABCB1—vagina—muscle cancer	0.000404	0.00739	CbGeAlD
Canagliflozin—Hyperkalaemia—Doxorubicin—muscle cancer	0.000396	0.00919	CcSEcCtD
Canagliflozin—Cystitis noninfective—Doxorubicin—muscle cancer	0.000394	0.00913	CcSEcCtD
Canagliflozin—Cystitis—Doxorubicin—muscle cancer	0.000389	0.00903	CcSEcCtD
Canagliflozin—Diabetes mellitus—Methotrexate—muscle cancer	0.000389	0.00901	CcSEcCtD
Canagliflozin—Urinary tract disorder—Etoposide—muscle cancer	0.000385	0.00894	CcSEcCtD
Canagliflozin—Photosensitivity—Methotrexate—muscle cancer	0.000385	0.00893	CcSEcCtD
Canagliflozin—Polyuria—Methotrexate—muscle cancer	0.000385	0.00893	CcSEcCtD
Canagliflozin—Urethral disorder—Etoposide—muscle cancer	0.000383	0.00887	CcSEcCtD
Canagliflozin—Infection—Dactinomycin—muscle cancer	0.000381	0.00883	CcSEcCtD
Canagliflozin—Blood urea increased—Doxorubicin—muscle cancer	0.000381	0.00883	CcSEcCtD
Canagliflozin—Vaginal infection—Doxorubicin—muscle cancer	0.000381	0.00883	CcSEcCtD
Canagliflozin—ABCB1—head—muscle cancer	0.000373	0.00683	CbGeAlD
Canagliflozin—Rash maculo-papular—Doxorubicin—muscle cancer	0.000366	0.0085	CcSEcCtD
Canagliflozin—Renal failure acute—Methotrexate—muscle cancer	0.000366	0.00849	CcSEcCtD
Canagliflozin—Bladder pain—Doxorubicin—muscle cancer	0.000365	0.00845	CcSEcCtD
Canagliflozin—Convulsion—Vincristine—muscle cancer	0.000363	0.00843	CcSEcCtD
Canagliflozin—ABCB1—testis—muscle cancer	0.00036	0.0066	CbGeAlD
Canagliflozin—Angiopathy—Etoposide—muscle cancer	0.000354	0.00821	CcSEcCtD
Canagliflozin—Infection—Vincristine—muscle cancer	0.00034	0.00789	CcSEcCtD
Canagliflozin—Diabetes mellitus—Doxorubicin—muscle cancer	0.000336	0.0078	CcSEcCtD
Canagliflozin—Nervous system disorder—Vincristine—muscle cancer	0.000336	0.00779	CcSEcCtD
Canagliflozin—Photosensitivity—Doxorubicin—muscle cancer	0.000333	0.00773	CcSEcCtD
Canagliflozin—Fatigue—Dactinomycin—muscle cancer	0.00033	0.00766	CcSEcCtD
Canagliflozin—Hypotension—Vincristine—muscle cancer	0.00032	0.00742	CcSEcCtD
Canagliflozin—Renal failure acute—Doxorubicin—muscle cancer	0.000317	0.00735	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000313	0.00727	CcSEcCtD
Canagliflozin—Breast disorder—Methotrexate—muscle cancer	0.000305	0.00708	CcSEcCtD
Canagliflozin—Abdominal pain—Dactinomycin—muscle cancer	0.000303	0.00702	CcSEcCtD
Canagliflozin—Hypoglycaemia—Doxorubicin—muscle cancer	0.0003	0.00695	CcSEcCtD
Canagliflozin—Loss of consciousness—Etoposide—muscle cancer	0.000299	0.00693	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Vincristine—muscle cancer	0.000296	0.00685	CcSEcCtD
Canagliflozin—Fatigue—Vincristine—muscle cancer	0.000295	0.00684	CcSEcCtD
Canagliflozin—Convulsion—Etoposide—muscle cancer	0.000294	0.00683	CcSEcCtD
Canagliflozin—Constipation—Vincristine—muscle cancer	0.000293	0.00679	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000287	0.00666	CcSEcCtD
Canagliflozin—Pancreatitis—Methotrexate—muscle cancer	0.000286	0.00664	CcSEcCtD
Canagliflozin—Hypersensitivity—Dactinomycin—muscle cancer	0.000282	0.00655	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Vincristine—muscle cancer	0.00028	0.00649	CcSEcCtD
Canagliflozin—Infection—Etoposide—muscle cancer	0.000276	0.00639	CcSEcCtD
Canagliflozin—Asthenia—Dactinomycin—muscle cancer	0.000275	0.00638	CcSEcCtD
Canagliflozin—Blood creatinine increased—Doxorubicin—muscle cancer	0.000274	0.00636	CcSEcCtD
Canagliflozin—Dehydration—Doxorubicin—muscle cancer	0.000272	0.00631	CcSEcCtD
Canagliflozin—Abdominal pain—Vincristine—muscle cancer	0.000271	0.00628	CcSEcCtD
Canagliflozin—Skin disorder—Etoposide—muscle cancer	0.000269	0.00625	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Doxorubicin—muscle cancer	0.000267	0.0062	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Methotrexate—muscle cancer	0.000267	0.00618	CcSEcCtD
Canagliflozin—Breast disorder—Doxorubicin—muscle cancer	0.000264	0.00613	CcSEcCtD
Canagliflozin—Hypotension—Etoposide—muscle cancer	0.000259	0.00601	CcSEcCtD
Canagliflozin—Hypersensitivity—Vincristine—muscle cancer	0.000252	0.00585	CcSEcCtD
Canagliflozin—Pancreatitis—Doxorubicin—muscle cancer	0.000248	0.00575	CcSEcCtD
Canagliflozin—Asthenia—Vincristine—muscle cancer	0.000246	0.0057	CcSEcCtD
Canagliflozin—Rash—Dactinomycin—muscle cancer	0.000242	0.0056	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Etoposide—muscle cancer	0.000239	0.00555	CcSEcCtD
Canagliflozin—Fatigue—Etoposide—muscle cancer	0.000239	0.00554	CcSEcCtD
Canagliflozin—Constipation—Etoposide—muscle cancer	0.000237	0.0055	CcSEcCtD
Canagliflozin—Pollakiuria—Doxorubicin—muscle cancer	0.000234	0.00542	CcSEcCtD
Canagliflozin—Urinary tract disorder—Methotrexate—muscle cancer	0.000231	0.00535	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Doxorubicin—muscle cancer	0.000231	0.00535	CcSEcCtD
Canagliflozin—Urethral disorder—Methotrexate—muscle cancer	0.000229	0.00532	CcSEcCtD
Canagliflozin—Nausea—Dactinomycin—muscle cancer	0.000228	0.00528	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Etoposide—muscle cancer	0.000227	0.00526	CcSEcCtD
Canagliflozin—Dizziness—Vincristine—muscle cancer	0.000226	0.00525	CcSEcCtD
Canagliflozin—Urticaria—Etoposide—muscle cancer	0.00022	0.00511	CcSEcCtD
Canagliflozin—Abdominal pain—Etoposide—muscle cancer	0.000219	0.00508	CcSEcCtD
Canagliflozin—Urinary tract infection—Doxorubicin—muscle cancer	0.000219	0.00508	CcSEcCtD
Canagliflozin—Rash—Vincristine—muscle cancer	0.000216	0.00501	CcSEcCtD
Canagliflozin—Dermatitis—Vincristine—muscle cancer	0.000216	0.005	CcSEcCtD
Canagliflozin—Angiopathy—Methotrexate—muscle cancer	0.000212	0.00492	CcSEcCtD
Canagliflozin—Hypersensitivity—Etoposide—muscle cancer	0.000204	0.00474	CcSEcCtD
Canagliflozin—Malnutrition—Methotrexate—muscle cancer	0.000204	0.00472	CcSEcCtD
Canagliflozin—Erythema—Methotrexate—muscle cancer	0.000204	0.00472	CcSEcCtD
Canagliflozin—Nausea—Vincristine—muscle cancer	0.000203	0.00472	CcSEcCtD
Canagliflozin—Urinary tract disorder—Doxorubicin—muscle cancer	0.0002	0.00464	CcSEcCtD
Canagliflozin—Asthenia—Etoposide—muscle cancer	0.000199	0.00461	CcSEcCtD
Canagliflozin—Urethral disorder—Doxorubicin—muscle cancer	0.000198	0.0046	CcSEcCtD
Canagliflozin—Pruritus—Etoposide—muscle cancer	0.000196	0.00455	CcSEcCtD
Canagliflozin—Angiopathy—Doxorubicin—muscle cancer	0.000184	0.00426	CcSEcCtD
Canagliflozin—Dizziness—Etoposide—muscle cancer	0.000183	0.00425	CcSEcCtD
Canagliflozin—Convulsion—Methotrexate—muscle cancer	0.000176	0.00409	CcSEcCtD
Canagliflozin—Erythema—Doxorubicin—muscle cancer	0.000176	0.00409	CcSEcCtD
Canagliflozin—Malnutrition—Doxorubicin—muscle cancer	0.000176	0.00409	CcSEcCtD
Canagliflozin—Rash—Etoposide—muscle cancer	0.000175	0.00405	CcSEcCtD
Canagliflozin—Dermatitis—Etoposide—muscle cancer	0.000175	0.00405	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000172	0.00399	CcSEcCtD
Canagliflozin—Infection—Methotrexate—muscle cancer	0.000165	0.00383	CcSEcCtD
Canagliflozin—Nausea—Etoposide—muscle cancer	0.000165	0.00382	CcSEcCtD
Canagliflozin—Nervous system disorder—Methotrexate—muscle cancer	0.000163	0.00378	CcSEcCtD
Canagliflozin—Skin disorder—Methotrexate—muscle cancer	0.000161	0.00374	CcSEcCtD
Canagliflozin—Syncope—Doxorubicin—muscle cancer	0.000158	0.00367	CcSEcCtD
Canagliflozin—Hypotension—Methotrexate—muscle cancer	0.000155	0.0036	CcSEcCtD
Canagliflozin—Loss of consciousness—Doxorubicin—muscle cancer	0.000155	0.00359	CcSEcCtD
Canagliflozin—Convulsion—Doxorubicin—muscle cancer	0.000153	0.00354	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000149	0.00346	CcSEcCtD
Canagliflozin—Dry mouth—Doxorubicin—muscle cancer	0.000147	0.0034	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000143	0.00333	CcSEcCtD
Canagliflozin—Fatigue—Methotrexate—muscle cancer	0.000143	0.00332	CcSEcCtD
Canagliflozin—Infection—Doxorubicin—muscle cancer	0.000143	0.00331	CcSEcCtD
Canagliflozin—Shock—Doxorubicin—muscle cancer	0.000142	0.00328	CcSEcCtD
Canagliflozin—Nervous system disorder—Doxorubicin—muscle cancer	0.000141	0.00327	CcSEcCtD
Canagliflozin—Skin disorder—Doxorubicin—muscle cancer	0.00014	0.00324	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Methotrexate—muscle cancer	0.000136	0.00315	CcSEcCtD
Canagliflozin—Hypotension—Doxorubicin—muscle cancer	0.000134	0.00312	CcSEcCtD
Canagliflozin—Urticaria—Methotrexate—muscle cancer	0.000132	0.00306	CcSEcCtD
Canagliflozin—Abdominal pain—Methotrexate—muscle cancer	0.000131	0.00305	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000124	0.00288	CcSEcCtD
Canagliflozin—Fatigue—Doxorubicin—muscle cancer	0.000124	0.00288	CcSEcCtD
Canagliflozin—Constipation—Doxorubicin—muscle cancer	0.000123	0.00285	CcSEcCtD
Canagliflozin—Hypersensitivity—Methotrexate—muscle cancer	0.000122	0.00284	CcSEcCtD
Canagliflozin—Asthenia—Methotrexate—muscle cancer	0.000119	0.00276	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000118	0.00273	CcSEcCtD
Canagliflozin—Pruritus—Methotrexate—muscle cancer	0.000118	0.00273	CcSEcCtD
Canagliflozin—Urticaria—Doxorubicin—muscle cancer	0.000114	0.00265	CcSEcCtD
Canagliflozin—Abdominal pain—Doxorubicin—muscle cancer	0.000114	0.00264	CcSEcCtD
Canagliflozin—Dizziness—Methotrexate—muscle cancer	0.00011	0.00255	CcSEcCtD
Canagliflozin—Hypersensitivity—Doxorubicin—muscle cancer	0.000106	0.00246	CcSEcCtD
Canagliflozin—Rash—Methotrexate—muscle cancer	0.000105	0.00243	CcSEcCtD
Canagliflozin—Dermatitis—Methotrexate—muscle cancer	0.000105	0.00243	CcSEcCtD
Canagliflozin—Asthenia—Doxorubicin—muscle cancer	0.000103	0.00239	CcSEcCtD
Canagliflozin—Pruritus—Doxorubicin—muscle cancer	0.000102	0.00236	CcSEcCtD
Canagliflozin—Nausea—Methotrexate—muscle cancer	9.87e-05	0.00229	CcSEcCtD
Canagliflozin—Dizziness—Doxorubicin—muscle cancer	9.51e-05	0.00221	CcSEcCtD
Canagliflozin—Rash—Doxorubicin—muscle cancer	9.07e-05	0.0021	CcSEcCtD
Canagliflozin—Dermatitis—Doxorubicin—muscle cancer	9.06e-05	0.0021	CcSEcCtD
Canagliflozin—Nausea—Doxorubicin—muscle cancer	8.54e-05	0.00198	CcSEcCtD
